Depressed patients are less responsive to chemotherapy

MyelomaLeave a comment

ESMO.- A brain-boosting protein plays an important role in how well people respond to chemotherapy. This is what reveals a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore. According to this research, cancer patients suffering depression have decreased amounts of brain-derived neurotrophic factor (BDNF) in their blood. Low levels make people less responsive to cancer drugs and less tolerant of their side-effects.

Addition of daratumumab to bortezomib and dexamethasone in patients with relapsed or refractory shows promising results in a phase III trial

MyelomaLeave a comment

At the ESMO 2016 Congress held in Copenhagen between 7th-11th October, Dr Katja Weissel, from the Haematology and Oncology Department of Medicine at University Hospital Tuebingen (Germany), presented the results of the CASTOR study, a phase III randomised controlled study of daratumumab, bortezomib and dexamethasone (DVd) compared with bortezomib and dexamethasone (Vd) in patients with relapsed or refractory myeloma.

Webinar on current myeloma diagnosis guidelines and techniques

MPE, MyelomaLeave a comment

Myeloma Patients Europe will hold an online webinar to provide an updated about the current myeloma diagnosis guidelines as well as a review of the current diagnosis techniques. The talk will be given by Dr Guy Pratt, Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust and Senior Lecturer in Haematology in the Institute of Immunology and Immunotherapy, University of Birmingham.

MPE encourages EMA to review its negative recommendation for ixazomib

Access, MPE, MyelomaLeave a comment

Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal of their decision on ixazomib.